To Participate in Clinical Trials or Medical Research Studies Click Here

Parkinson's Disease

Is Angiogenesis a Treatment and Potential Cure?

Zhittya Genesis Medicine is developing a drug, fibroblast growth factor 1 (FGF-1), to possibly treat Parkinson's disease by growing new blood vessels in ischemic tissue in the brain.

FGF-1 is a potent stimulator of angiogenesis (the growth of new blood vessels) and is capable of growing these new blood vessels in ischemic areas of the body, including the brain. Research has indicated that a lack of blood perfusion to dopamine producing neurons located in the substantia nigra region of the brain lead to a lack of dopamine and the classic symptoms of Parkinson's.

Zhittya has dosed over 130 patients suffering with Parkinson's disease in our medical research studies. Beyond demonstrating impressive safety data, it also improved the motor scores of all Parkinson's patients in the study. Some patients even reported feeling cognitive improvement in areas such as sleeping, memory, and clearer thinking.

Sign-Up for Clinical Trials and Medical Research Studies

The graph above shows preliminary results of our human patients' average potential motor skill improvements compared to the average decline in motor skills for people suffering from Parkinson's Disease over 6 months. The data above could indicate that FGF-1 has the ability to improve motor skills in individuals suffering from Parkinson's Disease in this group of ~100 participants.

In the past, FGF-1 has been able to grow new blood vessels in the human body. In a US FDA Phase IIA clinical trial, conducted at the University of Cincinnati, our drug was able to grow new blood vessels in the hearts of individuals with coronary artery disease, improving many of their symptoms.

FGF-1 has also shown excellent efficacy in treating Parkinson's disease in Cynomolgus monkey models. After being injected with a neurotoxin that selectively destroys dopamine-producing neurons, the two groups of monkeys came down with the classic symptoms of Parkinson's disease. After one group was administered FGF-1 and the other a placebo dose, the FGF-1 administered monkeys not only improved their motor scores almost to normal, but also increased their dopamine production and decreased their build up of alpha-synuclein plaque.

Zhittya Genesis Medicine has prepared multiple videos, listed below, discussing our possible treatment for Parkinson's disease. As mentioned above, Zhittya Genesis Medicine's most recent medical research studies in humans not only demonstrate that FGF-1 is safe when delivered intranasally, but hint at signs of efficacy, even showing a 20–80% improvement in motor scores following a month-long dosing period. Zhittya Genesis Medicine is currently conducting additional medical research studies and clinical trials in an effort to determine if FGF-1 is a possible remedy for the root cause of Parkinson's disease: diminished blood flow, leading to dysfunctional dopamine producing neurons.

This artist's illustration represents our understanding of FGF-1's role in the brains of Parkinson's disease patients. FGF-1 stimulates the division of blood vessel cells in ischemic regions, fostering regulated blood vessel growth to restore blood flow where needed most. Naturally occurring in the body, FGF-1 aids in regenerating blood vessels following injuries like cuts or bruises. It is well-tolerated, and our dosages have shown no adverse effects.

Earlier research, illustrated above, applied FGF-1 in growing new blood vessels in hearts affected by coronary artery disease during a US FDA Phase IIA clinical trial. It proved effective in vascular growth in ischemic heart regions, reducing angina and enhancing treadmill endurance. Zhittya hypothesis is that FGF-1, successful in heart treatments, could address Parkinson's disease by remedying the brain's blood flow deficiencies.

1/3

After receiving the neurotoxin MPTP, Cynomolgus monkeys exhibited classic Parkinson's disease symptoms, including reduced motor function and decreased dopamine levels, with increased alpha-synuclein plaque. At month 10, one group received FGF-1 while another got a placebo. Seven months later, the FGF-1 group showed nearly normal motor scores, unlike the placebo group, which worsened. Brain analyses revealed the FGF-1 group had higher dopamine production and less alpha-synuclein plaque. Zhittya now suggests FGF-1 could help Parkinson's patients by restoring blood flow to dopamine-producing brain areas, increasing dopamine and reducing synuclein aggregates.